Primary tabs

News

AWOL identifies novel chemotypes in the search for drugs to combat LF and onchocerciasis

From: LSTM

Snakebite envenoming

From: LSTM

Professor Janet Hemingway announces her intention to retire as Director of LSTM

From: LSTM

Research team at LSTM develop new ways to create and deliver medications for a wide range of immune-mediated neuropathies.

From: LSTM

LSTM at the Big Bang North West festival

From: LSTM

Global health diagnostics course attendees. Photo credited to the University of McGill.

A review of the McGill summer institute’s course in Global Health Diagnostics

New Publication: qRT-PCR assay for Chikungunya

MRC Confidence in Concept 2017: Awards announced

From: LSTM

Recipients of LSTM’s new Director’s Catalyst Fund announced

From: LSTM

LSTM’s A·WOL Consortium at Africa Oyé

From: LSTM

LSTM well represented at WL6

LSTM Seminar report: "Antimicrobial Resistance; it’s in you!"

From: LSTM

LSTM launches new Transposon Registry

From: LSTM

LSTM and partners develop molecule that could lead to first synthetic one-dose malaria treatment

From: LSTM

Evaluation of the FluoroType MTB test published in ERJ Open

LSTM faculties receive Athena SWAN Bronze Awards

From: LSTM

First molecular diagnostics for insecticide resistance in sandflies

From: LSTM

Photo from Left to right: Prof. Russell Stothard, Dr. Renata Candido and Prof. Tim St Pierre

Worms, Magnets and Diagnostics: Exploring new methods to diagnose egg-patent schistosomiasis

Liverpool drug discovery group generates a new series of inhibitors active against multi drug resistant (MDR) Mycobacterium tuberculosis via an MRC funded DPFS award (Biagini PI)

Our recent activities by LSTM people in the field of NTDs

From: LSTM

Medical Research Council Proximity to Discovery Fund

Credit: Alex Ribeiro

LSTM led study examines the venom system of a tiny fish with big teeth

From: LSTM

Statement from LSTM following the UK's formal announcement to leave the EU

From: LSTM

RCDD reports on a new way of screening potential treatments for tuberculosis

From: LSTM

Cross section filarial nematode wolbachia in green

New anti-Wolbachia drug regimen could reduce treatment times of lymphatic filariasis and onchocerciasis to 1-2 weeks

From: LSTM

MRC Confidence in Concept Fund 2016-2017 Now open for applications

From: LSTM

Noguchi Polio Trip

IVCC secure licence with Indian manufacturer for production of IQKs developed at LSTM

From: LSTM

Centre of Excellence in Infectious Diseases Research launched

From: LSTM

LSTM project receives a special mention in Access to Medicines Index 2016

From: LSTM

LSTM’s 117th Annual General Meeting

From: LSTM

Seminar Series Report: Systematic reviews of diagnostic test accuracy in infectious diseases.

From: LSTM

Seminar report: Mechanistic understanding to enable multi-targeting anti-infectives.

From: LSTM

LSTM’s Clinical Diagnostic Parasitology Laboratory (CDPL) receives UKAS accreditation

From: LSTM

New drug candidate for the curative treatment of onchocerciasis and lymphatic filariasis

From: LSTM

LSTM’s respiratory group looks at the effect of the new nasal spray flu vaccination on the carriage of pneumococcal bacteria in the nose.

From: LSTM

Seminar report: Neglected tropical diseases and LSTM

From: LSTM

Professor Janet Hemingway receives Honorary Doctor of Science from the University of Chester

From: LSTM

Seminar Series report: Tackling rheumatic heart disease - from antibiotics to ultrasound to ivermectin to vaccines

From: LSTM

Liverpool unveils world-class Knowledge Quarter vision

From: LSTM

Pages